Actualités sur Insurance

Suivre
Abonner Insurance
Filtre
  • 24.08.2021 – 12:02

    BMO Financial Group

    BMO Financial Group Reports Third Quarter 2021 Results

    Toronto (ots/PRNewswire) - BMO's Third Quarter 2021 Report to Shareholders, including the unaudited interim consolidated financial statements for the period ended July 31, 2021, is available online at www.bmo.com/investorrelations and at www.sedar.com. Financial Results Highlights Third Quarter 2021 Compared With Third Quarter 2020: - Net income of $2,275 million, an increase of 85%; adjusted net income1,4 of $2,292 ...

  • 10.08.2021 – 15:48

    Mindtree

    Mindtree Recognized with 2021 ISG Digital Case Study Award(TM)

    Bangalore, India and Warren, N.j. (ots/PRNewswire) - Mindtree's digital transformation work for four enterprise customers from diverse industry sectors adjudged best-in-class Mindtree, a global technology services and digital transformation company, has been recognized by Information Services Group (ISG), a leading global technology research and advisory firm, with the 2021 ISG Digital Case Study Award(TM) for its ...

  • 19.07.2021 – 13:00

    Solera Holdings, Inc.

    Solera to Acquire ENData

    Westlake, Tx (ots/PRNewswire) - Acquisition will extend Solera's global leadership in data and technology-enabled claims management solutions Solera Holdings, Inc. ("Solera"), a global leader in risk and asset management data and software solutions for the insurance and automotive industries, today announced that it has entered an agreement to acquire ENData Pty Ltd ("ENData"), a Brisbane, Australia-based insurance technology provider. ENData's data-driven property repairs ...

  • 25.02.2020 – 12:00

    BMO Financial Group

    BMO Financial Group Reports First Quarter 2020 Results

    Toronto (ots/PRNewswire) - Financial Results Highlights First Quarter 2020 Compared With First Quarter 2019: - Net income of $1,592 million and adjusted net income1 of $1,617 million, both up 5% - Reported EPS2 of $2.37 and adjusted EPS1 of $2.41, both up 4% - Revenue, net of CCPB3, of $6,031 million, up 8% - Provision for credit losses (PCL) of $349 million; includes PCL on performing loans of $25 million - ROE of 13.3%, ...

  • 05.02.2020 – 12:00

    Helsana Gruppe

    Helsana posts outstanding result for 2019

    Zürich (ots) - In 2019, Helsana Insurance Company Ltd recorded an outstanding result of CHF 436 million. This comprises a very strong investment performance and a solid underwriting result. Customer growth for 2020 once again clearly exceeded the prior year and the new corporate strategy was successfully launched at the start of 2020. In 2019, Helsana Insurance Company Ltd recorded an outstanding result of CHF 436 ...

  • 10.01.2020 – 14:05

    INFOSYS

    Infosys: Continued Momentum in Digital Drives 11.1% YTD Growth

    Bengaluru, India (ots/PRNewswire) - - FY 20 revenue guidance increased to 10.0%-10.5% "Q3 results further underscore that we remain steadfast in our journey of sustained client relevance and deepening engagement with them, as they partner with us in navigating their next in the digital transformation era", said Salil Parekh, CEO and MD. "For us, this has translated into double digit growth year-to-date, leading to an ...

  • 10.12.2019 – 09:00

    FintechOS

    FintechOS Raises GBP 10.7 Million (USD 14 Million) Series A for Global Expansion

    London (ots/PRNewswire) - New funding to support further growth in Europe and enable expansion to South East Asia and the US FintechOS (https://fintechos.com/), the next generation of hyper-personalised, automated financial technology, announced today it has secured GBP 10.7 million (USD 14 million) of Series A investment. The funding was led jointly by Earlybird ...

  • 22.11.2019 – 14:00

    Helsana Gruppe

    Quality-related problems concerning the prescription of medication / Helsana Drug Report

    Zurich (ots) - The medication costs in Switzerland amounted to about CHF 7.6 billion in 2018. Since 2010, costs have risen by 46 percent, whereby half of this increase was attributable to immunosuppressants and cancer medication. Great savings potential is above all associated with the use of biosimilars. One of the other findings of this year's Helsana Drug Report is ...